1Garland SM,Hernandez-Avila M,Wheeler CM,et al.Females united to unilaterally reduce endo/ectocervical disease(FUTURE I)investigators.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J].N Engl J Med,2007,356(3):1928-1943.
2Future ⅡStudy Group.Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions[J].N Engl J Med,2007,356(3):1915-1927.
3Susan L,Hendix DO.Assessing Human Papillomavirus Vaccine Efficacy and Safety[J].J Am Osteopath Assoc,2008,108(Suppl 2):8-12.
4Trimble CL,Peng S,Kos F,et al.A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3[J].Clin Cancer Res,2009,15(12):361-367.
5Tsen SW,Wu CY,Meneshian A,et al.Femtosecond laser treatment enhances DNA transfection efficiency in vivo[J].J Biomed Sci,2009,16(2):36.
6Klencke B,Matijevic M,Urban RG,et al.Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia:a Phase I study of ZYC101[J].Clin Cancer Res,2002,8(11):1028-1037.
7Maciag PC,Radulovic S,Rothman J.The first clinical use of a live-attenuated Listeria monocytogenes vaccine:a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix[J].Vaccine,2009,27(4):3975-3983.
8Kenter GG,Welters MJ,Valentijn AR,et al.Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in endstage cervical cancer patients shows low toxicity and robust immunogenicity[J].Clin Cancer Res,2008,14(22):169-177.
9Welters MJ,Kenter GG,Piersma SJ,et al.Induction of tumor-specific CD+4 and CD+8 T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine[J].Clin Cancer Res,2008,14(22):178-187.
